« prev   investing   next »



By mell following x   2017 Nov 3, 7:37am 124 views   0 comments   watch   quote     share    

Just received CRL from FDA for XYOSTED, their injectable testosterone, price crashed from almost $4 to sub $2. 50MM+ sales and rising, possible approval of generic epi-pen version in partnership w/ TEVA (ATRS supplies injectors). Risks are possible dilution (already bloated share count) if turnaround to profitability is delayed too much, otherwise this should slowly churn towards profitability within the next 1-2 years. Any movement on the CRL without the requirement of additional trials or approval of TEVAs generic epi-pen will send this soaring. Market cap just below 300MM, target market cap 700MM-1bln.

no comments found

Comment as anon_d6777 or log in at top of page: